Inhibition of HDAC3 has significantly reduced the viability of ERα-deficient endocrine-resistant BC cells, and the ERα/caspase 7/HDAC3 axis promotes the proliferation of endocrine-resistant BC cells that exhibit ERα loss [72]. This evidence concerns the gene HDAC3 and breast cancer.